Houston, TX Clinical Trials Report — June 2026

For Houston residents considering participation in clinical research, June 2026 presents a mix of urgent opportunities and significant new avenues for contributing to medical science. Across Houston, TX, a notable number of trials are nearing their enrollment deadlines, making prompt action essential for interested individuals.

A total of 156 clinical trials are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 13 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various cancers and other conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Advanced solid tumor (4 trials)
• Breast cancer (3 trials)
• Endometrial cancer (3 trials)
• Ovarian cancer (3 trials)
• Triple negative breast cancer (3 trials)
• Cancer (3 trials)
• Gastric cancer (3 trials)
• Primary peritoneal cancer (3 trials)
• Heart failure (3 trials)
• Myelodysplastic syndromes (3 trials)

New Research Opportunities Emerge in Houston

This month, Houston saw the opening of 46 new clinical trials, a slight decrease from the 53 trials that launched in May 2026. This brings the total number of actively recruiting clinical trials in Houston, TX, to 2,839 across 1,042 research facilities, underscoring the city's robust research landscape.

June brings several high-profile new trials to Houston, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is initiating a notable Phase 3 study, NCT07654361, "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This pivotal, multicenter, global, randomized, placebo-controlled, double-blind study aims for 3,600 participants to investigate the long-term efficacy, safety, and tolerability of aleniglipron once daily compared with placebo for weight management.
• Pfizer is sponsoring NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants." This Phase 3 study seeks 3,230 participants to learn about the safety and immune response of a new pneumococcal vaccine in infants.
• Also from Pfizer, NCT07660198, "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents," is a Phase 3 trial aiming for 1,200 participants. This study will assess the safety and immune response of a new pneumococcal vaccine in children and adolescents.
• Kallyope Inc. is leading NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This double-blind, randomized, multicenter, outpatient Phase 3 evaluation aims for 1,800 participants to assess the efficacy, safety, and tolerability of elismetrep compared with placebo for acute migraine treatment.
• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is also sponsoring NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)." This randomized, double-blind, placebo-controlled Phase 3 study seeks 1,100 participants to evaluate the long-term efficacy, safety, and tolerability of aleniglipron in individuals with overweight or obesity and Type 2 Diabetes Mellitus.
• The RTI International-sponsored study, NCT07625579, "Collaboration for Down Syndrome Progress (CDP)," is a long-term study following 1,400 people with Down syndrome of all ages to better understand their health, development, and everyday experiences.

New trials this month are exploring a range of conditions, with the most frequent being obesity (4 trials), overweight (3 trials), chronic weight management (2 trials), back pain (2 trials), and pneumococcal disease (2 trials). Drug trials account for the largest share of new studies, with 27 new drug trials, followed by 9 other study types and 7 device trials.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. A total of 4 of the 46 new trials launched this month are actively seeking healthy volunteers. Across Houston, a total of 196 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research. Remember, 13 of the trials closing soon also accept healthy volunteers, so prompt action is advised for those interested.

Houston's Leading Research Facilities

Houston is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• MD Anderson Cancer Center (394 trials)
• M D Anderson Cancer Center (276 trials)
• Baylor College of Medicine (181 trials)
• The University of Texas Health Science Center at Houston (136 trials)
• The University of Texas MD Anderson Cancer Center (133 trials)
• Houston Methodist Hospital (121 trials)
• Texas Children's Hospital (105 trials)
• University of Texas MD Anderson Cancer Center (84 trials)
• Research Site (81 trials)
• The University of Texas M. D. Anderson Cancer Center (68 trials)
• Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center (64 trials)
• UT MD Anderson Cancer Center (58 trials)

These institutions, particularly the various entities under the MD Anderson Cancer Center umbrella, specialize heavily in oncology research, while Baylor College of Medicine and The University of Texas Health Science Center at Houston offer broader medical research opportunities. Houston Methodist Hospital and Texas Children's Hospital also contribute significantly to the city's diverse research landscape.

Broadening Your Search: Nearby Options in Texas

While Houston offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Texas. Cities with active trials include San Antonio (28 trials), Dallas (24 trials), Austin (16 trials), Fort Worth (5 trials), McKinney (4 trials), El Paso (3 trials), Brownsville (3 trials), and Edinburg (3 trials). These options provide additional avenues for participation across the state.

Participation in clinical trials is open to a diverse range of individuals. Of the 46 new trials launched this month, 40 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 9 new trials include children, and 4 are female-only. Academic institutions continue to play a vital role in Houston's research ecosystem, with M.D. Anderson Cancer Center (11 trials) and The University of Texas Health Science Center, Houston (4 trials) sponsoring the most new studies. Industry sponsors like Novo Nordisk A/S (3 trials), Pfizer (2 trials), and Gasherbrum Bio, Inc. (2 trials) are also driving significant research efforts.

As we move through June, Houston's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.